Shanghai Runda Med Tech Co
Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables; medical solutions to help healthcare professionals in the areas of diabetes, POCT, clinical chemistry, and immunoassay; professional technica… Read more
Shanghai Runda Med Tech Co (603108) - Net Assets
Latest net assets as of June 2025: CN¥5.38 Billion CNY
Based on the latest financial reports, Shanghai Runda Med Tech Co (603108) has net assets worth CN¥5.38 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.79 Billion) and total liabilities (CN¥8.41 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.38 Billion |
| % of Total Assets | 39.03% |
| Annual Growth Rate | 27.97% |
| 5-Year Change | 37.35% |
| 10-Year Change | 503.54% |
| Growth Volatility | 43.4 |
Shanghai Runda Med Tech Co - Net Assets Trend (2014–2024)
This chart illustrates how Shanghai Runda Med Tech Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Runda Med Tech Co (2014–2024)
The table below shows the annual net assets of Shanghai Runda Med Tech Co from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.60 Billion | +2.88% |
| 2023-12-31 | CN¥5.45 Billion | +8.73% |
| 2022-12-31 | CN¥5.01 Billion | +14.07% |
| 2021-12-31 | CN¥4.39 Billion | +7.64% |
| 2020-12-31 | CN¥4.08 Billion | +16.03% |
| 2019-12-31 | CN¥3.52 Billion | +12.31% |
| 2018-12-31 | CN¥3.13 Billion | +13.91% |
| 2017-12-31 | CN¥2.75 Billion | +23.69% |
| 2016-12-31 | CN¥2.22 Billion | +139.31% |
| 2015-12-31 | CN¥928.55 Million | +95.23% |
| 2014-12-31 | CN¥475.63 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Runda Med Tech Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 669.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.34 Billion | 53.64% |
| Other Components | CN¥2.02 Billion | 46.36% |
| Total Equity | CN¥4.35 Billion | 100.00% |
Shanghai Runda Med Tech Co Competitors by Market Cap
The table below lists competitors of Shanghai Runda Med Tech Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Founder Motor Co Ltd
SHE:002196
|
$783.79 Million |
|
Noah Holdings Ltd
NYSE:NOAH
|
$783.86 Million |
|
Shanghai SMI Holding Co Ltd
SHG:600649
|
$784.03 Million |
|
BioLife Solutions Inc
NASDAQ:BLFS
|
$784.06 Million |
|
Transmissora Aliança de Energia Elétrica S.A
SA:TAEE3
|
$783.46 Million |
|
Anhui Shanying Paper Industry Co Ltd
SHG:600567
|
$783.39 Million |
|
Suzhou Sushi Testing Instrument Co Ltd
SHE:300416
|
$783.37 Million |
|
FIRST RESOURCES LTD O.N.
F:5F1
|
$783.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Runda Med Tech Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,280,104,992 to 4,354,582,007, a change of 74,477,015 (1.7%).
- Net income of 55,280,608 contributed positively to equity growth.
- Dividend payments of 337,343,818 reduced retained earnings.
- Other factors increased equity by 356,540,225.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥55.28 Million | +1.27% |
| Dividends Paid | CN¥337.34 Million | -7.75% |
| Other Changes | CN¥356.54 Million | +8.19% |
| Total Change | CN¥- | 1.74% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Runda Med Tech Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.02x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.69x to 2.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥3.95 | CN¥14.57 | x |
| 2018-12-31 | CN¥4.32 | CN¥14.57 | x |
| 2019-12-31 | CN¥4.76 | CN¥14.57 | x |
| 2020-12-31 | CN¥5.53 | CN¥14.57 | x |
| 2021-12-31 | CN¥5.97 | CN¥14.57 | x |
| 2022-12-31 | CN¥6.71 | CN¥14.57 | x |
| 2023-12-31 | CN¥7.17 | CN¥14.57 | x |
| 2024-12-31 | CN¥7.21 | CN¥14.57 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Runda Med Tech Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.67%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 3.29x
- Recent ROE (1.27%) is below the historical average (9.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 15.81% | 5.61% | 1.24x | 2.28x | CN¥27.62 Million |
| 2015 | 9.93% | 5.63% | 0.96x | 1.83x | CN¥-641.67K |
| 2016 | 5.50% | 5.38% | 0.53x | 1.94x | CN¥-95.30 Million |
| 2017 | 9.58% | 5.08% | 0.61x | 3.12x | CN¥-9.52 Million |
| 2018 | 10.45% | 4.39% | 0.79x | 3.01x | CN¥11.40 Million |
| 2019 | 11.22% | 4.39% | 0.78x | 3.27x | CN¥33.67 Million |
| 2020 | 10.30% | 4.67% | 0.69x | 3.18x | CN¥9.64 Million |
| 2021 | 10.98% | 4.29% | 0.74x | 3.47x | CN¥33.96 Million |
| 2022 | 10.74% | 3.98% | 0.72x | 3.73x | CN¥28.91 Million |
| 2023 | 6.39% | 2.99% | 0.64x | 3.34x | CN¥-154.71 Million |
| 2024 | 1.27% | 0.67% | 0.58x | 3.29x | CN¥-380.18 Million |
Industry Comparison
This section compares Shanghai Runda Med Tech Co's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,767,087,259
- Average return on equity (ROE) among peers: 6.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Runda Med Tech Co (603108) | CN¥5.38 Billion | 15.81% | 1.56x | $783.77 Million |
| Berry Genomics Co Ltd (000710) | $108.87 Million | -46.67% | 1.22x | $377.87 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $9.50 Billion | 15.09% | 1.22x | $1.14 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $1.70 Billion | 17.66% | 0.10x | $317.93 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $308.32 Million | 33.58% | 0.53x | $283.14 Million |
| Maccura Biotechnology Co Ltd (300463) | $4.54 Billion | 21.06% | 0.45x | $576.46 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $4.05 Billion | -16.18% | 0.14x | $319.65 Million |
| BGI Genomics Co Ltd (300676) | $4.25 Billion | 9.09% | 0.23x | $1.45 Billion |
| Amoy Diagnostics Co Ltd (300685) | $307.91 Million | 21.77% | 0.15x | $834.75 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.82 Billion | -6.01% | 0.44x | $226.85 Million |
| SMO ClinPlus Co. Ltd. (301257) | $1.08 Billion | 12.47% | 0.26x | $347.98 Million |